We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
-25.8%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$388M
AUM Growth
-$159M
Cap. Flow
+$19.4M
Cap. Flow %
5.02%
Top 10 Hldgs %
90.41%
Holding
17
New
1
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$14.7M
2
KRYS icon
Krystal Biotech
KRYS
+$5.23M

Top Sells

Rank Stock Value
1
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$525K
2
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$76

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
1
AnaptysBio
ANAB
$1.7B
$148M 38.13%
2,316,447
– –
APTX
2
DELISTED
Aptinyx Inc. Common Stock
APTX
$52.8M 13.61%
3,190,079
– –
COLL icon
3
Collegium Pharmaceutical
COLL
$820M
$32.4M 8.36%
1,887,332
– –
GRTS
4
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$31.9M 8.22%
2,061,758
-4
-0% -$76
IOVA icon
5
Iovance Biotherapeutics
IOVA
$3.74B
$19.4M 5%
2,188,331
– –
KRYS icon
6
Krystal Biotech
KRYS
$10.6B
$18.2M 4.69%
875,000
+250,000
+40% +$5.23M
ALNA
7
DELISTED
Allena Pharmaceuticals
ALNA
$18.2M 4.68%
3,330,373
– –
TPST icon
8
Tempest Therapeutics
TPST
$17.9M
$11.1M 2.86%
+7,162
New +$14.7M
SRRA
9
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$10.7M 2.76%
202,803
– –
ALPN
10
DELISTED
Alpine Immune Sciences Inc
ALPN
$8.09M 2.09%
2,199,011
– –
ITRM
11
DELISTED
Iterum Therapeutics
ITRM
$7.71M 1.99%
102,554
– –
SYBX
12
DELISTED
Synlogic
SYBX
$6.07M 1.57%
57,694
– –
KZR
13
DELISTED
Kezar Life Sciences
KZR
$5.9M 1.52%
25,000
– –
NBRV
14
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$5.86M 1.51%
16,049
-977
-6% -$525K
ETTX
15
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$5.49M 1.42%
1,349,953
– –
CDTX
16
DELISTED
Cidara Therapeutics
CDTX
$3.08M 0.8%
65,613
– –
BLCM
17
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$3.07M 0.79%
105,144
– –

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q4 2018 Portfolio in Review

As of Q4 2018, Frazier Management held 17 positions worth $388M, down 29% from $546M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Frazier Management deployed $19.4M of net new capital in Q4 2018, opening 1 new position and adding to 1 existing holding. Its largest new stake was Tempest Therapeutics: 7,162 shares worth $11.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Nabriva Therapeutics plc Ordinary Shares Ireland, an estimated $525K trimmed.

  • Frazier Management's largest Q4 2018 buy was Tempest Therapeutics: 7,162 shares worth $11.1M.
  • Frazier Management added most to Krystal Biotech in Q4 2018, an estimated $5.23M increase.
  • Frazier Management's biggest Q4 2018 reduction was Nabriva Therapeutics plc Ordinary Shares Ireland, cutting an estimated $525K.
  • Frazier Management's ten largest holdings make up 90% of its $388M portfolio in Q4 2018.
  • Frazier Management opened 1 new position and closed 0 in Q4 2018.
  • Frazier Management's portfolio value fell 29% quarter-over-quarter to $388M.

Based on Frazier Management's 13F filing for Q4 2018, filed 11 Feb 2019.